JP2007502789A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502789A5
JP2007502789A5 JP2006523576A JP2006523576A JP2007502789A5 JP 2007502789 A5 JP2007502789 A5 JP 2007502789A5 JP 2006523576 A JP2006523576 A JP 2006523576A JP 2006523576 A JP2006523576 A JP 2006523576A JP 2007502789 A5 JP2007502789 A5 JP 2007502789A5
Authority
JP
Japan
Prior art keywords
active substance
characteristic
mass
concentration
drying gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502789A (ja
JP2007502789A6 (ja
Filing date
Publication date
Priority claimed from DE2003138402 external-priority patent/DE10338402A1/de
Application filed filed Critical
Publication of JP2007502789A publication Critical patent/JP2007502789A/ja
Publication of JP2007502789A6 publication Critical patent/JP2007502789A6/ja
Publication of JP2007502789A5 publication Critical patent/JP2007502789A5/ja
Pending legal-status Critical Current

Links

JP2006523576A 2003-08-18 2004-08-12 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用 Pending JP2007502789A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003138402 DE10338402A1 (de) 2003-08-18 2003-08-18 Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402.2 2003-08-18
PCT/EP2004/009012 WO2005018603A2 (de) 2003-08-18 2004-08-12 Sprühgetrocknetes, amorphes bibn 4096, verfahren zu dessen herstellung sowie dessen verwendung als inhalativum

Publications (3)

Publication Number Publication Date
JP2007502789A JP2007502789A (ja) 2007-02-15
JP2007502789A6 JP2007502789A6 (ja) 2007-05-10
JP2007502789A5 true JP2007502789A5 (enExample) 2007-09-27

Family

ID=34201781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523576A Pending JP2007502789A (ja) 2003-08-18 2004-08-12 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用

Country Status (5)

Country Link
EP (1) EP1663149A2 (enExample)
JP (1) JP2007502789A (enExample)
CA (1) CA2536047A1 (enExample)
DE (1) DE10338402A1 (enExample)
WO (1) WO2005018603A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (enExample) 2006-02-22 2015-07-10 Mannkind Corp
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX373764B (es) * 2013-06-19 2020-03-24 Aic246 Ag & Co Kg Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral.
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum

Similar Documents

Publication Publication Date Title
JP2007502789A5 (enExample)
JP2007502789A6 (ja) 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用
JP2007502789A (ja) 噴霧乾燥された無定形bibn4096、その調製方法及び吸入剤としてのその使用
US20050043247A1 (en) Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
TWI468190B (zh) 具有改良之安定性的(z)-2-氰基-3-羥基-丁-2-烯酸-(4’-三氟甲基苯基)-醯胺錠劑調配物
JP5680898B2 (ja) 苦味を抑制した速崩壊錠
US9511026B2 (en) Poorly soluble drug containing microspheres with improved bioavailability and method of preparing the same
US6692768B1 (en) Preparation method of drug-containing spherical fine particles
TWI538676B (zh) 非晶(5-氟-2-甲基-3-喹啉-2-基甲基-吲哚-1-基)-乙酸
JP5075832B2 (ja) 肺高血圧を処置するためのジアリールウレア
DE102009015702A1 (de) Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
JP4444626B2 (ja) 口腔内崩壊錠
JP2005538934A (ja) Cgrp拮抗剤bibn4096の塩を含有する吸入粉末の調製方法
JP2008013480A (ja) 薬物含有微粒子およびその製造方法
JP2007502790A5 (enExample)
ES2657482T3 (es) Formulación de polvo estable que contiene un agente anticolinérgico
US20050042178A1 (en) Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
JP4493594B2 (ja) 粉末経鼻投与製剤
JP2007502790A (ja) Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
JP2007502790A6 (ja) Cgrpアンタゴニスト1−〔n2−〔3,5−ジブロモ−n−〔〔4−(3,4−ジヒドロ−2(1h)−オキソキナゾリン−3−イル)−1−ピペリジニル〕カルボニル〕−d−チロシル〕−l−リシル〕−4−(4−ピリジニル)−ピペラジンを含む微粒子、その調製方法及び吸入粉末としてのその使用
CN105440017B (zh) 达比加群酯香草酸盐及其制备方法和应用
JP2007502791A5 (enExample)
JP2010510278A5 (enExample)
JP2010510278A (ja) 新規抗コリン作用薬を含有する安定な粉末製剤
JP2007502792A5 (enExample)